Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 27 November 1981:
Vol. 214. no. 4524, pp. 1026 - 1028
DOI: 10.1126/science.6171035
Prev | Table of Contents | Next

Articles

Science, Vol 214, Issue 4524, 1026-1028
Copyright © 1981 by American Association for the Advancement of Science

articles

Intrathecal interferon reduces exacerbations of multiple sclerosis

L Jacobs, J O'Malley, A Freeman, and R Ekes

Ten patients with multiple sclerosis who were treated with human fibroblast interferon (IFN-B) for 6 months showed a significant reduction in their exacerbation rates compared with their rates before treatment (P < .01). The IFN-B was administered intrathecally by serial lumbar punctures. There was no significant change in the exacerbation rates of ten multiple sclerosis control patients before and during the period of observation. The IFN-B recipients have now been on the study a mean of 1.5 years, the controls, 1.2 years. The clinical condition of five of the IFN-B recipients and one of the control patients has improved, whereas the condition of five of the controls and one of the IFN-B recipients has deteriorated (P < .036). These findings warrant cautious optimism about the efficacy of intrathecal IFN-B in altering the course of multiple sclerosis and support concepts of a viral or dysimmune etiology of the disease.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Antigen-Specific Blockade of Lethal CD8 T-Cell Mediated Autoimmunity in a Mouse Model of Multiple Sclerosis.
S.-Y. Na, H. Eujen, K. Gobel, S. G. Meuth, K. Martens, H. Wiendl, and T. Hunig (2009)
J. Immunol. 182, 6569-6575
   Abstract »    Full Text »    PDF »
Hematopoietic cell-derived interferon controls viral replication and virus-induced disease.
P. A. Lang, L. Cervantes-Barragan, A. Verschoor, A. A. Navarini, M. Recher, M. Pellegrini, L. Flatz, A. Bergthaler, K. Honda, B. Ludewig, et al. (2009)
Blood 113, 1045-1052
   Abstract »    Full Text »    PDF »
Lawrence D. Jacobs, MD (1938-2001).
R. Rudick, B. Weinstock-Guttman, and F. Munschauer (2002)
Neurology 58, 999-1000
   Full Text »    PDF »
Reason for hope: the advent of disease-modifying therapies in multiple sclerosis.
P. W. O'Connor (2000)
Can. Med. Assoc. J. 162, 83-84
   Full Text »    PDF »
Interferon beta and the cytokine trail.
H. Moses Jr. and S. Sriram (1999)
Neurology 52, 1729
   Full Text »    PDF »
{blacktriangledown}Interferon beta-1b - hope or hype?.
(1996)
DTB 34, 9-11
   Abstract »    Full Text »    PDF »
Betaseron for Multiple Sclerosis: Implications for Therapeutics.
R. A. Rudick (1994)
Arch Neurol 51, 125-128
   Abstract »    PDF »
Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis: Results of a Multicenter, Double-blinded Study.
L. Jacobs, A. M. Salazar, R. Herndon, P. A. Reese, A. Freeman, R. Jozefowicz, A. Cuetter, F. Husain, W. A. Smith, R. Ekes, et al. (1987)
Arch Neurol 44, 589-595
   Abstract »    PDF »
Systemic Recombinant {alpha}-2Interferon Therapy in Relapsing Multiple Sclerosis.
D. L. Camenga, K. P. Johnson,, M. Alter, C. D. Engelhardt, P. S. Fishman, J. I. Greenstein, A. S. Haley, R. L. Hirsch, J. E. Kleiner, V. Y. Kofie, et al. (1986)
Arch Neurol 43, 1238-1246
   Abstract »    PDF »
Intrathecal Interferon in the Treatment of Multiple Sclerosis: Patient Follow-up.
L. Jacobs, J. A. O'Malley, A. Freeman, R. Ekes, and P. A. Reese (1985)
Arch Neurol 42, 841-847
   Abstract »    PDF »
Systemic Interferon Therapy for Multiple Sclerosis: Design of a Trial.
K. P. Johnson (1983)
Arch Neurol 40, 681-682
   Abstract »    PDF »
Intrathecal Interferon as Treatment of Multiple Sclerosis: A Planned Multicenter Study.
L. Jacobs, J. A. O'Malley, A. Freeman, and P. Reese (1983)
Arch Neurol 40, 683-686
   Abstract »    PDF »
Interferon.
R. Jatte (1983)
Arch Neurol 40, 391-392
   Abstract »    PDF »
Intrathecal Interferon in Multiple Sclerosis.
L. Jacobs, J. O'Malley, A. Freeman, J. Murawski, and R. Ekes (1982)
Arch Neurol 39, 609-615
   Abstract »    PDF »
Intrathecal interferon for multiple sclerosis.
C. Berry (1982)
Science 217, 269-270
   PDF »
Intrathecal Interferon for Multiple Sclerosis.
L. JACOBS, J. O'MALLEY, A. FREEMAN, and R. EKES (1982)
Science 217, 270
   PDF »
Rapid evolution of RNA genomes.
J Holland, K Spindler, F Horodyski, E Grabau, S Nichol, and S VandePol (1982)
Science 215, 1577-1585
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)